New antiplatelet drug Kengreal approved by US FDA

New antiplatelet drug Kengreal approved by US FDA

FDA approves new antiplatelet drug used during heart procedure – The U.S. Food and Drug Administration approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart.

Stenting early better than medical therapy alone

Early use of stents better than medical therapy alone for certain patients – For patients with stable coronary artery disease who have at least one narrowed blood vessel that compromises flow to the heart, medical therapy alone leads to a significantly higher risk of hospitalization and the urgent need for a coronary stent when compared with therapy that also includes initial placement of artery-opening stents.

Stent design may put patients at risk of heart attack

A new stent design may put patients at risk – Stent shortening – a newly observed deformity in cases using a particular family of stents, can cause serious complications for patients, says researchers. In this case the stent clotted off and the patient had a heart attack.

Stroke clinical trial finds intensive medical treatment better than brain stent

Intensive medical therapy more effective than stenting for preventing a second stroke — Results of NIH-funded clinical trial published in New England Journal of Medicine – Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the medical treatment, a large nationwide clinical trial has shown.

Coronary artery bypass graft surgeries decreasing in US

Rate of Coronary Artery Bypass Graft Surgeries Decreases Substantially – Between 2001 and 2008, the annual rate of coronary artery bypass graft surgeries performed in the United States decreased by more than 30 percent, but rates of percutaneous coronary interventions (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) did not change significantly.

Evidence based treatments decrease risk of death among heart attack patients

Increase in Use of Evidence-Based Treatments is Followed By Decrease in Risk of Death Among Patients With Heart Attack – In an analysis of data from a coronary care registry in Sweden, between 1996-2007 there was an increase in the prevalence of use of evidence-based invasive procedures and pharmacological therapies for treatment of a certain type of heart attack, and a decrease in the rate of death at 30 days and one year after a heart attack for these patients.

Effient to reduce heart attack risk in angioplasty patients

The U.S. Food and Drug Administration (FDA) Approves Effient to Reduce the Risk of Heart Attack in Angioplasty Patients. – The U.S. Food and Drug Administration has approved the Eli Lilly’s blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery.

Certain drug coated stents may be safe, effective

Certain drug-coated stents may be safe, effective option for elderly patients – Stents coated with the drug paclitaxel may be a safe, effective treatment option for coronary artery disease (CAD) patients age 70 and older and shouldn’t be withheld due to advanced patient age, according to a study reported in Circulation: Cardiovascular Interventions.

Benefits of anti clotting medications reduced by heartburn drugs

Study shows benefits of anti-clotting medications reduced by common heartburn drugs. Proton pump inhibitors interfere with anti-clotting protection of clopidogrel. – The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

Drug eluting stents prove more effective

Study conducted by the Cardiovascular Research Foundation is published in the New England Journal of Medicine; Largest randomized comparison of drug-eluting and bare-metal stents ever performed. – The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in The New England Journal of Medicine.

Health Newstrack